Reportable Segment and Major Customers Information (Tables)

9 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Consolidated Net Revenues

Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment revenues during any of the three- and nine-month periods ended June 30, 2021 and 2020 were as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
	2021			2020			2021			2020
Diagnostics
Customer A		10	%		13	%		11	%		11	%
Customer B		11	%		8	%		10	%		13	%
Customer C		14	%		5	%		12	%		5	%
Life Science
Customer D		3	%		23	%		4	%		17	%
Customer E		4	%		14	%		12	%		11	%

In addition, during the three and nine months ended June 30, 2021, the Life Science segment’s ten largest customers, including their affiliates, accounted for approximately 46% and 43%, respectively, of Life Science segment revenues, and 24% and 27%, respectively, of consolidated revenues.

Reportable segment Information

Reportable segment information for the interim periods is as follows:

	Diagnostics			Life Science		Corporate(1)			Eliminations(2)			Total
Three Months Ended June 30, 2021
Net revenues -
Third-party	$	31,189		$	32,322	$	—		$	—		$	63,511
Inter-segment		100			54		—			(154	)		—
Operating income		2,510			16,129		(2,998	)		39			15,680
Goodwill (June 30, 2021)		95,267			20,048		—			—			115,315
Other intangible assets, net (June 30, 2021)		76,743			1		—			—			76,744
Total assets (June 30, 2021)		329,003			117,564		—			3			446,570
Three Months Ended June 30, 2020
Net revenues -
Third-party	$	21,598		$	63,199	$	—		$	—		$	84,797
Inter-segment		86			56		—			(142	)		—
Operating income		(1,783	)		39,305		(2,849	)		(8	)		34,665
Goodwill (September 30, 2020)		94,855			19,331		—			—			114,186
Other intangible assets, net (September 30, 2020)		83,179			18		—			—			83,197
Total assets (September 30, 2020)		306,812			98,483		—			(34	)		405,261
Nine Months Ended June 30, 2021
Net revenues -
Third-party	$	93,459		$	148,233	$	—		$	—		$	241,692
Inter-segment		285			163		—			(448	)		—
Operating income		3,749			92,015		(11,286	)		67			84,545
Nine Months Ended June 30, 2020
Net revenues -
Third-party	$	91,331		$	98,183	$	—		$	—		$	189,514
Inter-segment		264			176		—			(440	)		—
Operating income		8,087			51,564		(7,832	)		31			51,850

(1)  Includes selected legal costs of $438 and $2,695 in the three and nine months ended June 30, 2021, respectively, and $134 and $1,189 in the three and nine months ended June 30, 2020, respectively.

(2)  Eliminations consist of inter-segment transactions.

Pre-tax Earnings Table

A reconciliation of reportable segment operating income to consolidated earnings before income taxes for the interim periods is as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
	2021			2020			2021			2020
Operating income:
Diagnostics segment	$	2,510		$	(1,783	)	$	3,749		$	8,087
Life Science segment		16,129			39,305			92,015			51,564
Eliminations		39			(8	)		67			31
Total segment operating income		18,678			37,514			95,831			59,682
Corporate operating expenses		(2,998	)		(2,849	)		(11,286	)		(7,832	)
Interest income		—			3			15			137
Interest expense		(444	)		(703	)		(1,450	)		(2,002	)
RADx initiative grant income		—			—			1,000			—
Other, net		59			908			(1,515	)		1,561
Consolidated earnings before income taxes	$	15,295		$	34,873		$	82,595		$	51,546